Skip to content
Doctor licensed in Poland · PWZ 3211301 Prescription on the EU model Every day, 5am to 11pm (Irish time)

Weight loss injections: how GLP-1 treatment works and is assessed

Weight loss injections are GLP-1 based medicines that you inject under the skin, once a week or once a day, alongside changes to what you eat and how active you are. This page explains what they contain, who they are licensed for, how the dose is built up, which side effects to expect and what a doctor checks before writing a prescription, whether you are starting treatment or continuing it.

What GLP-1 medicines are

GLP-1 (glucagon-like peptide-1) is a hormone produced in the body, and its receptor is present in areas of the brain involved in regulating appetite and food intake. GLP-1 receptor agonists are medicines that bind to and activate this receptor. Semaglutide and liraglutide work this way: their summaries of product characteristics (SmPCs) describe them as GLP-1 analogues with 94% and 97% sequence homology to human GLP-1. Tirzepatide is different, because it is a long-acting agonist at two receptors, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1.

The SmPCs describe the effect on eating in similar terms: these medicines increase feelings of fullness and satiety and reduce hunger, so you eat less. They also slow the emptying of the stomach, which explains several of their side effects and some of their interactions with tablets taken by mouth. They are licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them.

The three substances and how they are taken

Three active substances are licensed for weight management as injections. The table summarises how each is taken and how the dose is built up, from section 4.2 of each SmPC. Every weight management licence for these products on the HPRA list falls in category A, meaning a prescription is needed and it may not be renewed.

SubstanceHow it is takenWeight management licence (SmPC 4.1)Dose steps (SmPC 4.2)
SemaglutideInjection once a week; for adults also a tablet once a dayAdults; the injection also for adolescents aged 12 and overInjection: 0.25 mg in weeks 1-4, then 0.5 mg, 1 mg and 1.7 mg, reaching 2.4 mg after 16 weeks; 7.2 mg is possible after at least 4 weeks on 2.4 mg in adults who started with a BMI of 30 or more. Tablet: 1.5 mg, then 4 mg, 9 mg and 25 mg, at least 4 weeks per step
TirzepatideInjection once a weekAdults (tirzepatide is also licensed for type 2 diabetes)2.5 mg for 4 weeks, then 5 mg; further increases in 2.5 mg steps after at least 4 weeks on a dose; maintenance 5 mg, 10 mg or 15 mg, maximum 15 mg
LiraglutideInjection once a dayAdults; also adolescents aged 12 and over and children aged 6 to under 12, with weight criteria0.6 mg, rising by 0.6 mg at intervals of at least a week to 3.0 mg a day; daily doses above 3.0 mg are not recommended

One substance, two different licences

Semaglutide is also the active substance of a separate product licensed only for adults with type 2 diabetes that is not controlled well enough, as an addition to diet and exercise. Its SmPC lists no weight management indication, and its weekly doses go up to 2 mg, so it is not the same treatment as the semaglutide product licensed for weight management. Using the diabetes product for weight loss alone falls outside its licence.

The substance pages explain each medicine in more detail: our page on semaglutide for weight management, which also covers the diabetes product, our page on tirzepatide and our page on liraglutide.

Who these medicines are licensed for

For adults, the weight management licences of all three substances start from the same point: an initial body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 to under 30 kg/m² together with at least one weight-related health problem. Examples in the SmPCs include prediabetes or type 2 diabetes, obstructive sleep apnoea, high blood pressure and abnormal blood fats (dyslipidaemia), and cardiovascular disease is also named in the semaglutide and tirzepatide SmPCs.

Every one of these licences pairs the medicine with a reduced-calorie diet and an increase in physical activity. For semaglutide and tirzepatide the licence covers both weight loss and weight maintenance. The licences for younger people differ between products and have their own criteria, which this page does not cover in detail. The doctor decides whether a medicine is right for you; reaching the BMI threshold does not by itself lead to a prescription.

How the dose is built up

Each of these medicines starts at a low dose that is raised in steps. The semaglutide SmPC says the escalation is there to reduce the likelihood of gastrointestinal symptoms, and the liraglutide SmPC says the weekly steps improve gastrointestinal tolerability. If a step causes significant stomach symptoms, the semaglutide SmPC allows the increase to be delayed or the previous dose to be used until things improve, while the liraglutide SmPC suggests considering stopping treatment if a step is not tolerated for two weeks in a row.

For the weekly injections, each step has its own pen strength; the daily liraglutide pen is set to the dose you need. That is why the doctor needs to know which step you are on when you ask to continue treatment.

Missed doses are handled differently. A missed weekly semaglutide injection can be given within 5 days and a missed tirzepatide injection within 4 days; after that you skip it and keep your usual injection day. A missed daily liraglutide dose can still be taken within 12 hours of the usual time. Your package leaflet is the reference for the pen you use.

Side effects you should know about

The most frequently reported side effects of all three substances are gastrointestinal: nausea, diarrhoea, vomiting, constipation and abdominal pain. The SmPCs describe them as mostly mild or moderate and seen mainly in the first weeks of treatment or while the dose is being increased. Other side effects listed include indigestion, reflux, burping, wind, a bloated feeling, tiredness and dizziness. Hair loss is listed as common with semaglutide and tirzepatide; with semaglutide it was reported more often in people who lost 20% of their weight or more.

Some warnings apply to the whole group. Nausea, vomiting and diarrhoea can cause dehydration, which in rare cases has led to worse kidney function, so the SmPCs advise you to avoid losing too much fluid. Acute pancreatitis has been reported: severe pain in the stomach that does not go away, sometimes reaching the back, needs a doctor straight away, and the medicine is stopped if pancreatitis is suspected. Gallstones are listed as common with semaglutide and liraglutide and as uncommon with tirzepatide.

Before an operation under general anaesthesia or deep sedation, tell the team that you use one of these medicines: food can stay in the stomach for longer, and cases of stomach contents being inhaled into the lungs have been reported.

There are also points specific to one substance or one group of patients. The semaglutide SmPC reports an increased risk of a very rare condition affecting the optic nerve (NAION) and says a sudden loss of vision needs an eye examination. If you have type 2 diabetes and use insulin or a sulphonylurea, the risk of low blood sugar rises and the dose of those medicines may need to be lowered. The liraglutide SmPC asks for the heart rate to be checked at regular intervals, because liraglutide can raise it.

Pregnancy, breastfeeding and contraception

None of these medicines is recommended during pregnancy. If you want to become pregnant, or become pregnant during treatment, the medicine is stopped. Because they stay in the body for a long time, the SmPCs ask for semaglutide to be stopped at least 2 months before a planned pregnancy and tirzepatide at least 1 month before. Women who could become pregnant are advised by both SmPCs to use contraception during treatment.

On breastfeeding the product information differs: semaglutide and liraglutide should not be used while breastfeeding, while the tirzepatide SmPC says tirzepatide could be considered for use during breastfeeding.

The contraceptive pill is a common concern. In the tirzepatide study, a single dose lowered the peak levels of the pill hormones, but the SmPC says this reduction is not considered clinically relevant and no dose adjustment of oral contraceptives is required. The semaglutide SmPC says semaglutide is not expected to make oral contraceptives less effective, and the liraglutide SmPC expects the contraceptive effect to be unaffected.

The liraglutide SmPC also notes that diarrhoea may affect the absorption of medicines taken by mouth, so if you vomit or have severe diarrhoea, check the leaflet of your contraceptive. Contraception during weight management is covered on our page on contraception during weight loss treatment.

When the doctor may decline or ask for more

The doctor assesses your answers against the product information and your own history. Depending on the substance, the SmPCs advise caution, or do not recommend use, in situations such as a history of pancreatitis, severe gastrointestinal disease or severe gastroparesis, type 1 diabetes, use of another weight management product, severe kidney or liver disease, severe heart failure, pregnancy or a planned pregnancy. A BMI below the licensed threshold is another reason the doctor may decline.

Before deciding, the doctor can request medical records, test results or a measurement such as your blood pressure; he can also recommend an in-person examination or turn the request down. If you already use one of these medicines, the doctor needs the substance, your current dose and how long you have been on it, so that any prescription fits the step of the schedule you have reached.

Symptoms that need in-person care

A written assessment cannot replace an examination, and some symptoms need medical help in person, not a new prescription:

  • Severe pain in your stomach, sometimes going through to your back, that does not go away.
  • Vomiting or diarrhoea that stops you keeping fluids down.
  • A sudden loss of vision or a sudden change in your sight.
  • Swelling of your face, lips or throat, or difficulty breathing.
  • Low blood sugar you cannot treat yourself, if you have diabetes.

Where to go for urgent care

In an emergency, phone 112 or 999 or go to your nearest emergency department (ED). For anything that needs an examination but is not an emergency, start with your GP. If your GP surgery is closed, its recorded message should tell you how to reach the local out-of-hours GP service.

How Weight Loss Treatment works

Weight Loss Treatment covers both starting a weight management medicine and continuing one you already use. The medical questionnaire asks you to describe your situation or name the medicine, and to answer questions on your health, other medicines and existing conditions. The doctor's assessment of your answers is a written one. There is no video call and no telephone consultation.

If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. Documents the doctor asks for, such as a letter from the clinic that started your treatment or a recent test result, you send through the chat. Paying does not commit the doctor to prescribing. We give no turnaround time.

What Weight Loss Treatment costs

The Weight Loss Treatment fee is 29,90 €. The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full.

For 7,90 €, priority handling places your request earlier in the queue without making the assessment any shorter. Our fee covers the doctor's assessment; you pay for the medicine at the pharmacy, at the pharmacy's price. We make no claim about whether a medicine dispensed on this prescription counts towards a medical card or the Drugs Payment Scheme. We do not quote medicine prices, so ask the pharmacy what the pen and strength on your prescription will cost.

Your prescription and the pharmacy

If the doctor issues a prescription, you receive it as a PDF by email. You print the PDF and take the printout to a pharmacy. A pharmacist in Ireland decides whether to dispense a prescription written by a doctor in another EEA country and may decline. This is not an Irish ePrescription and it is not sent through Healthmail.

Guidance issued by the Pharmaceutical Society of Ireland permits a pharmacist to dispense on a prescription from elsewhere in the EEA, subject to certain conditions, if the medicine is authorised in Ireland and is not classed as a controlled drug. The details such a prescription must carry under Irish rules include your full name, with your first name written in full, and your date of birth. Medicines are not sold or posted by us; according to the HPRA, selling prescription medicines online is illegal in Ireland.

Who assesses your request

Damian Wojno, a doctor registered in Poland (licence no. 3211301, Regional Medical Chamber in Olsztyn), carries out the assessment. He is not on the register of the Irish Medical Council. He works from your written answers, from anything you send through the chat and from the product information of the medicine concerned. The assessment does not replace care from your own GP, who knows your history and can examine you.

What are GLP-1 weight loss injections?

They are medicines that act on the GLP-1 receptor, which is involved in regulating appetite and food intake. Semaglutide and liraglutide are GLP-1 receptor agonists, and tirzepatide acts on both the GIP and the GLP-1 receptors. Semaglutide and tirzepatide are injected once a week and liraglutide once a day, and semaglutide is also licensed as a daily tablet for adults. Each is meant to be combined with a reduced-calorie diet and increased physical activity.

Who can get weight loss injections in Ireland?

For adults, the licences apply from a BMI of 30 or more, or from 27 to under 30 where there is at least one weight-related condition, for example prediabetes, obstructive sleep apnoea or high blood pressure. Every licence of these weight management products in the HPRA list is prescription only (category A). Whether treatment is suitable for you is for the doctor to decide; a BMI at or above the threshold does not on its own lead to a prescription.

Can I continue an injection that another doctor started?

You can request a continuation through Weight Loss Treatment. Tell the doctor the substance, your current dose and when you started, and send any letter or earlier prescription the doctor asks for through the chat in your account. The doctor assesses a continuation in the same way as a new request and may decline.

Do weight loss injections stop the contraceptive pill working?

The product information does not expect any of the three to make the pill less effective, and the tirzepatide SmPC says no dose adjustment of oral contraceptives is required. For women who could become pregnant, contraception during treatment is recommended in the semaglutide and tirzepatide SmPCs.

Will an Irish pharmacy dispense my prescription?

No one can say in advance. A pharmacist in Ireland decides whether to dispense a prescription written by a doctor in another EEA country and may decline. After a prescription is issued, you print the PDF and bring the printout with you. Guidance from the Pharmaceutical Society of Ireland says that a prescription shown on a phone would not be considered appropriate.

Is the diabetes semaglutide pen licensed for weight loss?

No. That product is licensed only for adults whose type 2 diabetes is not controlled well enough, alongside diet and exercise, with weekly doses up to 2 mg. The semaglutide product licensed for weight management is a separate product, with its own dose schedule up to 2.4 mg a week, or 7.2 mg in some adults, and a daily tablet form.